These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 24731537)

  • 1. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation.
    Savović J; Weeks L; Sterne JA; Turner L; Altman DG; Moher D; Higgins JP
    Syst Rev; 2014 Apr; 3():37. PubMed ID: 24731537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The judgement of biases included in the category "other bias" in Cochrane systematic reviews of interventions: a systematic survey.
    Babic A; Pijuk A; Brázdilová L; Georgieva Y; Raposo Pereira MA; Poklepovic Pericic T; Puljak L
    BMC Med Res Methodol; 2019 Apr; 19(1):77. PubMed ID: 30971219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor reliability between Cochrane reviewers and blinded external reviewers when applying the Cochrane risk of bias tool in physical therapy trials.
    Armijo-Olivo S; Ospina M; da Costa BR; Egger M; Saltaji H; Fuentes J; Ha C; Cummings GG
    PLoS One; 2014; 9(5):e96920. PubMed ID: 24824199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of use and adequacy of Cochrane risk of bias tool 2 in non-Cochrane systematic reviews published in 2020: Meta-research study.
    Babić A; Barcot O; Visković T; Šarić F; Kirkovski A; Barun I; Križanac Z; Ananda RA; Fuentes Barreiro YV; Malih N; Dimcea DA; Ordulj J; Weerasekara I; Spezia M; Žuljević MF; Šuto J; Tancredi L; Pijuk A; Sammali S; Iascone V; von Groote T; Poklepović Peričić T; Puljak L
    Res Synth Methods; 2024 May; 15(3):430-440. PubMed ID: 38262609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.
    Cook JA; Hislop J; Adewuyi TE; Harrild K; Altman DG; Ramsay CR; Fraser C; Buckley B; Fayers P; Harvey I; Briggs AH; Norrie JD; Fergusson D; Ford I; Vale LD
    Health Technol Assess; 2014 May; 18(28):v-vi, 1-175. PubMed ID: 24806703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disagreements in risk of bias assessment for randomized controlled trials in hypertension-related Cochrane reviews.
    Yao Y; Shen J; Luo J; Li N; Liao X; Zhang Y
    Trials; 2024 Jun; 25(1):405. PubMed ID: 38907276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adequacy of risk of bias assessment in surgical vs non-surgical trials in Cochrane reviews: a methodological study.
    Barcot O; Boric M; Dosenovic S; Cavar M; Jelicic Kadic A; Poklepovic Pericic T; Vukicevic I; Vuka I; Puljak L
    BMC Med Res Methodol; 2020 Sep; 20(1):240. PubMed ID: 32993499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application.
    Minozzi S; Cinquini M; Gianola S; Gonzalez-Lorenzo M; Banzi R
    J Clin Epidemiol; 2020 Oct; 126():37-44. PubMed ID: 32562833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of bias judgments for random sequence generation in Cochrane systematic reviews were frequently not in line with Cochrane Handbook.
    Barcot O; Boric M; Poklepovic Pericic T; Cavar M; Dosenovic S; Vuka I; Puljak L
    BMC Med Res Methodol; 2019 Aug; 19(1):170. PubMed ID: 31382898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool.
    Bilandzic A; Fitzpatrick T; Rosella L; Henry D
    PLoS Med; 2016 Apr; 13(4):e1001987. PubMed ID: 27046153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions.
    Tonin FS; Lopes LA; Rotta I; Bonetti AF; Pontarolo R; Correr CJ; Fernandez-Llimos F
    Int J Clin Pharm; 2019 Jun; 41(3):785-792. PubMed ID: 30963446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the evaluation of risk of bias in periodontology and implant dentistry comprehensive? A systematic review.
    Faggion CM; Listl S; Alarcón MA
    J Clin Periodontol; 2015 May; 42(5):488-94. PubMed ID: 25809114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common challenges and suggestions for risk of bias tool development: a systematic review of methodological studies.
    Tomlinson E; Cooper C; Davenport C; Rutjes AWS; Leeflang M; Mallett S; Whiting P
    J Clin Epidemiol; 2024 Jul; 171():111370. PubMed ID: 38670243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the risk of performance and detection bias in Cochrane reviews as a joint domain is less accurate compared to two separate domains.
    Barcot O; Boric M; Dosenovic S; Puljak L
    BMC Med Res Methodol; 2021 Jul; 21(1):149. PubMed ID: 34275437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-articular hyaluronic acid injection in treating knee osteoarthritis: assessing risk of bias in systematic reviews with ROBIS tool.
    Xing D; Wang B; Zhang W; Yang Z; Hou Y; Chen Y; Lin J
    Int J Rheum Dis; 2017 Nov; 20(11):1658-1673. PubMed ID: 29044993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Bias in Iranian Randomized Trials Included in Cochrane Reviews.
    Kabir A; Sofi-Mahmudi A; Karimi Behnagh A; Eidkhani V; Baradaran HR; Kabiri P; Haghdoost A; Mesgarpour B
    Arch Iran Med; 2022 Jun; 25(6):375-382. PubMed ID: 35943017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons.
    Nejadghaderi SA; Balibegloo M; Rezaei N
    Health Sci Rep; 2024 Jun; 7(6):e2165. PubMed ID: 38835932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of bias and magnitude of effect in orthodontic randomized controlled trials: a meta-epidemiological review.
    Koletsi D; Spineli LM; Lempesi E; Pandis N
    Eur J Orthod; 2016 Jun; 38(3):308-12. PubMed ID: 26174770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.